
Impel NeuroPharma: A Seattle-based medical firm innovating CNS disease therapies via unique nasal drug delivery.
Impel Pharmaceuticals, founded in Seattle, Washington, is dedicated to creating innovative therapies for central nervous system (CNS) diseases. The company's core mission is to address unmet medical needs through transformative treatments. Impel's flagship product is based on their proprietary POD™ device, a novel nasal drug delivery platform designed to administer medication directly to the upper nasal cavity, enhancing efficacy and patient outcomes.
Notable figures associated with Impel Pharmaceuticals include key investors from the biotech and pharmaceutical sectors. The company has achieved significant milestones, including the successful development and commercialization of its unique drug delivery system. Impel's impact lies in its ability to offer new hope and improved quality of life for patients with challenging CNS conditions, positioning itself as a disruptive force in the pharmaceutical industry.

Neurana Pharmaceuticals
neuranapharma.com

Supernus Pharmaceuticals
supernus.com

ARS Pharmaceuticals
ars-pharma.com

PIN Pharma
pinpharma.com

PleoPharma
pleopharma.com

Bryn Pharma
brynpharma.com

Avalyn Pharma
avalynpharma.com

Aptinyx
aptinyx.com

Durect
durect.com

Collegium Pharmaceutical

Edison Pharmaceuticals

Amphastar Pharmaceuticals
amphastar.com

Aquestive Therapeutics
aquestive.com

Vanda Pharmaceuticals

Woolsey Pharmaceuticals
woolseypharma.com
Companies similar to Impel Pharmaceuticals include Neurana Pharmaceuticals, Supernus Pharmaceuticals, ARS Pharmaceuticals and PIN Pharma.
Impel Pharmaceuticals was founded in 2008.
Impel Pharmaceuticals' headquarters is located in Seattle, WA, US.
Impel Pharmaceuticals has 119 employees as of Feb 6, 2024.